Pitolisant is safe and effective when used to reduce daytime sleepiness over 1 year in adults with OSA, with or without CPAP treatment.

**STUDY DESIGN**

- Included all adults (both pitolisant and placebo arms) from short-term HAROSA randomized controlled trials (RCTs)
- Participants offered pitolisant up to week 52
- Primary efficacy outcome: Epworth Sleepiness Scale (ESS) score between baseline and week 52
- Safety outcomes: Treatment-emergent adverse event(s) (TEAE[s]), serious TEAEs, and special interest TEAEs

**RESULTS**

- **376 of 512**
  Adults included in HAROSA RCTs completed 1-year follow-up

- **-8.0 [-8.3, -7.5]**
  The pooled mean difference in ESS score from baseline to 1 year for the intention-to-treat sample

- **35.1%, 2.0%, and 11.1%**
  The overall proportions of TEAE, serious TEAE, and TEAE of special interest
  
  **No cardiovascular safety issues were reported**

*Pitolisant is safe and effective when used to reduce daytime sleepiness over 1 year in adults with OSA, with or without CPAP treatment.*


Copyright © 2024 American College of Chest Physicians